Utility of Piperine and Liquisolid Tablets to Enhance the Pharmacological Profile of Tacrolimus
DOI:
https://doi.org/10.22317/jcms.v10i6.1674Keywords:
Tacrolimus; Bioenhancer; Calcineurin inhibitors; Immunosuppressant; Self-nano emulsifying drug delivery system; Liquisolid tabletsAbstract
Objective: To evaluate the impact of a self-nanoemulsifying drug delivery system (SNEDDS) incorporated into liquisolid tablets (LSTs) and the natural bioenhancer piperine (Pip) on the bioavailability, immunosuppressive efficacy, and toxicity of tacrolimus (Tac).
Methods: An optimized Tac-SNEDDS was developed and formulated into four LST compositions using various carriers and coatings (Neusilin®-Avicel®/FujiSil®-fumed silica). The optimal Tac-LST formulation was selected based on drug content and tested in Wistar rats. Bioavailability was assessed using the limited area under the curve (AUC₀₋₆), while immunosuppressive efficacy was evaluated through IL-2 levels. Renal histology and serum cystatin C levels were analyzed to assess potential nephrotoxicity.
Results: Among the four Tac-LST formulations, LST-4 (Avicel®/FujiSil®) exhibited the highest drug content and was chosen for in vivo studies. Co-administration of Pip, LSTs, and their combination significantly improved Tac bioavailability without compromising immunosuppressive activity. Pip co-administration demonstrated superior IL-2 inhibition compared to Tac alone or Tac-LSTs. Additionally, Pip reduced Tac-induced increases in serum cystatin C levels and mitigated renal histological damage, indicating a nephroprotective effect. The combination of Pip and Tac-LSTs provided the most stable absorption profile with minimal AUC fluctuations, suggesting a more predictable pharmacokinetic profile.
Conclusion: Pip and LST formulations significantly enhance Tac bioavailability while maintaining its immunosuppressive efficacy. Moreover, Pip exhibits a protective effect against Tac-induced nephrotoxicity. The combination of Pip and Tac-LSTs offers a stable pharmacokinetic profile, potentially improving therapeutic outcomes by maintaining consistent drug levels.
References
Brunet, M. and M. Pastor-Anglada (2022). “Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics.” Pharmaceutics 14(9): 1755.
Peterson, B., M. Weyers, J. H. Steenekamp, J. D. Steyn, C. Gouws and J. H. Hamman (2019). “Drug bioavailability enhancing agents of natural origin (bioenhancers) that modulate drug membrane permeation and presystemic metabolism.” Pharmaceutics 11(1): 33.
Haq, I. U., M. Imran, M. Nadeem, T. Tufail, T. A. Gondal and M. S. Mubarak (2021). “Piperine: A review of its biological effects.” Phytotherapy Research 35(2): 680–700.
Wang, Y., J. Sun, T. Zhang, H. Liu, F. He and Z. He (2011). “Enhanced oral bioavailability of tacrolimus in rats by self-microemulsifying drug delivery systems.” Drug Development and Industrial Pharmacy 37(10): 1225–1230.
Nekkanti, V., J. Rueda, Z. Wang and G.V. Betageri (2016). “Design, characterization, and in vivo pharmacokinetics of tacrolimus proliposomes.” AAPS PharmSciTech 17(5): 1019–1029.
Bobbala, S.K.R. and P.R. Veerareddy (2012). “Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery.” Journal of Liposome Research 22(4): 285–294.
Rehman, F.U., K.U. Shah, S.U. Shah, I.U. Khan, G.M. Khan and A. Khan (2017). “From nanoemulsions to self-nanoemulsions, with recent advances in selfnanoemulsifying drug delivery systems (SNEDDS).” Expert Opin Drug Deliv 14(11): 1325–1340.
Mohanty, S., S. Sahoo, S. Patra and B.M. Sahoo (2022). “Self-micro emulsifying drug delivery systems: State-of-art a technology to enhance the solubility of poorly water-soluble drug.” Journal of Medical Pharmaceutical and Allied Sciences, 11(6): 5368–5374.
Seo, E.B., L.H. du Plessis and J.M. Viljoen (2022). “Solidification of Self-Emulsifying Drug Delivery Systems as a Novel Approach to the Management of Uncomplicated Malaria.” Pharmaceuticals 15(2): 120.
Patel, J., Němcová, L., Maguire, P., Graham, W. G., & Mariotti, D. (2013). Synthesis of surfactant-free electrostatically stabilized gold nanoparticles by plasma-induced liquid chemistry. Nanotechnology, 24(24), 245604.
Thakur, P.S., N. Singh, A.T. Sangamwar and A.K. Bansal (2017). “Investigation of Need of Natural Bioenhancer for a Metabolism Susceptible Drug Raloxifene, in a Designed Self-Emulsifying Drug Delivery System.” AAPS PharmSciTech 18(7): 2529–2540.
Diehl, R., F. Ferrara, C. Müller, A.Y. Dreyer, D.D. McLeod, S. Fricke and J. Boltze (2017). “Immunosuppression for in vivo research: State-of-the-art protocols and experimental approaches.” Cellular & Molecular Immunology 14(2): 146–179.
Kumar-Sarangi, M., Chandra-Joshi, B., & Ritchie, B. (2018). Natural bioenhancers in drug delivery: An overview. Puerto Rico health sciences journal, 37(1), 12–18.
Zhang, Y., M. Huo, J. Zhou and S. Xie (2010). “PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel.” Computer Methods and Programs in Biomedicine 99(3): 306–314.
Dheer, D., P.N. Gupta and R. Shankar (2018). “Tacrolimus: An updated review on delivering strategies for multifarious diseases.” European Journal of Pharmaceutical Sciences 114: 217–227.
Alqahtani, M.S., M. Kazi, M.A. Alsenaidy and M.Z. Ahmad (2021). “Advances in oral drug delivery.” Frontiers in Pharmacology 12: 618411.
Garud, A.A. and R.R. Shah (2017). “Formulation and optimization of liquisolid tablets of olmesartan medoxomil using 3 (2) factorial design.” International Journal of Pharmaceutical Sciences and Research 8(11):4682–4693.
Lu, M., H. Xing, J. Jiang, X. Chen, T. Yang, D. Wang and P. Ding (2017). “Liquisolid technique and its applications in pharmaceutics.” Asian Journal of Pharmaceutical Sciences 12(2): 115–123.
Meçule, A., F. Tinti, A. Bachetoni, L. Poli, M. D’Alessandro, C. Alessandri, I. Umbro, I. Nofroni, P. Berloco and A. Mitterhofer (2011). Interleukin-2 profiles shortly after tacrolimus conversion from a twice-daily to once-daily regimen. Transplantation proceedings, Elsevier 43(4):1017–9.
Aboul-Einien, M. (2012). “Design and in-Vitro Evaluation of Olanzapine-Loaded Self Nanoemulsifying Drug Delivery System.” Int. J. Ind. Pharm. Life Sci 2: 12–32.
Almeida‐Paulo, G.N., R. Lubomirov, N.L. Alonso‐Sanchez, L. Espinosa‐Román, C. Fernández Camblor, C. Díaz, G. Muñoz Bartola and A.J. Carcas‐Sansuán (2014). “Limited sampling strategies for tacrolimus exposure (AUC 0‐24) prediction after Prograf® and Advagraf® administration in children and adolescents with liver or kidney transplants.” Transplant International 27(9):939–948.
El-Say, K.M., O.A. Ahmed, B.M. Aljaeid and A.S. Zidan (2017). “Matrix-type transdermal films to enhance simvastatin ex vivo skin permeability.” Pharmaceutical Development and Technology 22(4): 492–499.
Gorgani, L., Mohammadi, M., Najafpour, G. D., & Nikzad, M. (2017). Piperine—the bioactive compound of black pepper: from isolation to medicinal formulations. Comprehensive reviews in food science and food safety, 16(1), 124–140.
Dudhatra, G.B., S.K. Mody, M.M. Awale, H.B. Patel, C.M. Modi, A. Kumar, D.R. Kamani and B.N. Chauhan (2012). “A comprehensive review on pharmacotherapeutics of herbal bioenhancers.” The Scientific World Journal 2012: 637953.
Lim, T.Y. and M. Heneghan (2016). “Biomarkers of immunosuppression.” Clinical Liver Disease 8(2): 34.
Pan, Y., B. Hu, M. Li, L. Fan, Y. Ni, J. Zhou and X. Shi (2014). “A meta-analysis on diagnostic value of serum cystatin C and creatinine for the evaluation of glomerular filtration function in renal transplant patients.” African Health Sciences 14(4): 1025–1035.
Kakalij, R.M., B.D. Kumar and P.V. Diwan (2016). “Comparative evaluation of nephroprotective potential of resveratrol and piperine on nephrotic BALB/c mice.” Indian Journal of Pharmacology 48(4): 382.
Sudjarwo, S.A., K. Eraiko and G.W. Sudjarwo (2017). “Protective effects of piperine on lead acetate induced-nephrotoxicity in rats.” Iranian Journal of Basic Medical Sciences 20(11): 1227.
Luo, K., S.W. Lim, J. Jin, L. Jin, H.W. Gil, D.S. Im, H.S. Hwang and C.W. Yang (2019). “Cilastatin protects against tacrolimus-induced nephrotoxicity via anti-oxidative and anti-apoptotic properties.” BMC Nephrology 20(1): 1–11.
Hošková, L., I. Málek, L. Kopkan and J. Kautzner (2017). “Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension.” Physiological Research 66(2): 167.
Lee, M.-K. (2020). “Liposomes for enhanced bioavailability of water-insoluble drugs: In vivo evidence and recent approaches.” Pharmaceutics 12(3): 264.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
